Global leaders in vaccine innovation today announced the advancement of an mRNA-based vaccine candidate preventing both influenza and COVID-19 to a Phase 1 clinical trial.
The Pfizer Inc. and BioNTech SE vaccine candidate aims to address these severe respiratory diseases with one vaccine.
The vaccine candidate combines Pfizer's quadrivalent modRNA-based influenza vaccine candidate, qIRV (22/23), which is currently in Phase 3 clinical development, and Pfizer and BioNTech's authorized Omicron-adapted bivalent COVID-19 BNT162b2 (Original/Omicron BA.4/BA.5) vaccine.
mRNA-Based Influenza and COVID-19 Combo Vaccine Candidate Launches Study
mRNA-Based Influenza and COVID-19 Combo Vaccine Candidate Launches Study
Global leaders in vaccine innovation today announced the advancement of an mRNA-based vaccine candidate preventing both influenza and COVID-19 to a Phase 1 clinical trial.
The Pfizer Inc. and BioNTech SE vaccine candidate aims to address these severe respiratory diseases with one vaccine.
The vaccine candidate combines Pfizer's quadrivalent modRNA-based influenza vaccine candidate, qIRV (22/23), which is currently in Phase 3 clinical development, and Pfizer and BioNTech's authorized Omicron-adapted bivalent COVID-19 BNT162b2 (Original/Omicron BA.4/BA.5) vaccine.
Physicians Say Faulty Oxygen Devices Put Lives in Peril
Speaking to an expert panel during an FDA hearing, physicians cast doubt on the accuracy of pulse oximeters
AI Algorithm May ID Dysfunctional Immune Profiles in Acute Infection
Machine learning framework used to deploy quantitative sepsis response signature score, which was estimated using seven- or 12-gene signature
Pain at Age 44 Linked to Subsequent Pain, Poor General Health
Chronic pain at age 44 years linked to poor mental health outcomes, pessimism about future, joblessness at age 55 years
Worsening BP Outcomes Seen in HTN Patients During Pandemic
Systolic and diastolic BP increased by 1.79 and 1.30 mm Hg, respectively, during pandemic versus prepandemic period